Navigation Links
FavId in Medical News

Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting

New Product Name Also Unveiled in Ongoing Preparation for Commercial Launch SAN DIEGO, Dec. 6 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, announced that new data, including f...
FavId in Medical Technology

Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkin's Lymphoma in Europe

Data Reported at the Congress of the European Hematology Association SAN DIEGO, June 11, 2007 /PRNewswire-FirstCall/ -- Favrille, Inc. , a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, announced interim data from a Phase 2 clinical trial...

Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results

...domized, double-blind, placebo controlled trial of favid following Rituxan(R) treatment in patients with fo... patients were randomly assigned to receive either favid plus Leukine(R) (sargramostim, GM-CSF) or placebo ...etic information extracted from a patient's tumor. favid is currently under investigation in a pivotal Phas...

Favrille Announces Results From Study Showing Enhanced Activity From Insect Cell-Derived Immunotherapy for Lymphoma

...ing them potentially more active as well." About favid favid is a patient-specific, Id/KLH active immunotherapy...nrollment in its pivotal Phase 3 clinical trial of favid following Rituxan(R) induction therapy in patients...
FavId in Biological Technology

Favrille Announces $21.1 Million Registered Direct Offering

...etic information extracted from a patient's tumor. favid is currently under investigation in a pivotal Phas... development, testing, manufacturing and marketing favid or Favrille's other product candidates; delays in ...can serve as the basis for accelerated approval of favid and whether it will receive expedited review as a ...

Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference

...diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. favid is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-ce...

Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007

...eases of the immune system. The Company's lead product candidate, FavId(R), is based upon unique genetic information extracted from a patient's tumor. favid is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell non-Hodgkin's lymphoma (NHL) and Phase 2 clin...

Favrille to Present at BIO InvestorForum

...diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. favid is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-ce...

Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum

...diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. favid is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-ce...

Favrille CEO to Present at Bear Stearns Healthcare Conference

...diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. favid is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-ce...

Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference

...diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. favid is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-ce...
Other Tags
(Date:12/20/2014)... Parker & Sons, Inc. a focused ... experience in contractor services announces reaching a milestone by ... homeowners of Arizona. Parker and Sons is comprised of ... that make customer service the number one priority. The ... started with one service vehicle and has since grown ...
(Date:12/19/2014)... 2014 Sweetdressy.com , a leading ... its newest selection of cheap prom dresses for ladies ... in the world and clients can buy these dresses ... prom dresses feature cool cuts and delicate craftsmanship, and ... the middle-end market. Discount shipping costs are available for ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Silver Dollar ... official world record -- for the first time ever, Silver ... record book, Guinness World Records 2015, listing the park’s wood ... Roller Coaster. In additional awards announced this week, Silver Dollar ... Christmas Lights in the US,” USA Today’s 10Best awards for ...
(Date:12/19/2014)... December 20, 2014 An evening dress is ... a lady’s closet. Discount-Dress.com, a distinguished dresses retailer, has unveiled ... beautiful dresses in this great shopping platform. Customers can ... the staff's hard work, Discount-Dress.com has been accepted and praised ... faster and easier shopping stage for clients. In order to ...
(Date:12/19/2014)... -- The intestinal bacteria that cause inflammatory bowel disease, ... inherited, researchers report. The findings, published recently in ... efforts to prevent the disease and treat the 1.6 ... added. "The intestinal bacteria, or ,gut microbiome, you ... big impact on your health for the rest of ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 2Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 3Health News:Cheap Prom Dresses Online Now at Sweetdressy.com 2Health News:Silver Dollar City Nets New Titles: Guinness Book of World Records, Plus CNN Travel, USA Today & Fodor’s Top Places for Christmas Lights 2Health News:Attractive Evening Dresses Announced by Discount-Dress.com 2Health News:Crohn's, Colitis May Have Genetic Underpinnings, Study Finds 2
(Date:11/18/2014)... , Nov. 18, 2014  The Secure ... Industry Association today jointly announce the formation of ... release of its Identity and Biometric Entry ... The Framework received official support from BORDERPOL, the ... to improve and provide expertise regarding border security, ...
(Date:11/18/2014)...   EyeLock Inc. , a market leader ... USA (Safran), a leading U.S. provider of ... partnership to offer comprehensive biometric identity solutions and ... screening and financial services markets. As ... through a nationwide network of 1,100 IdentoGO® Centers.  ...
(Date:11/11/2014)... 2014  Forensicon, Inc., a Chicago ... announce the promotion of Yaniv Schiff from ... In Schiff,s new role as Director, he will lead ... forensics examiners and provide leadership within the company,s digital ... http://photos.prnewswire.com/prnh/20141110/157719 Schiff joined Forensicon in ...
Breaking Biology News(10 mins):Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
Other Contents